While the US Food and Drug Administration addressed cybersecurity in premarket submissions in 2014 and then again with an updated guidance in 2018, the agency now says an “updated approach” is needed to meet the demands of heightened cyber risks.
Issued on 8 April, the FDA’s new draft guidance, “